Tempus AI (NASDAQ:TEM) Stock Price Down 6.1% – Time to Sell?

Tempus AI, Inc. (NASDAQ:TEM) fell 6.1% on Thursday. The stock traded as low as $77.30 and last traded at $76.8740. Approximately 3,388,758 shares were traded during mid-day trading, a decline of 45% from the average daily volume of 6,146,030 shares. The stock had previously closed at $81.90.

Analyst Ratings Changes

Several research analysts recently commented on TEM shares. Needham & Company LLC reissued a “buy” rating and issued a $75.00 price objective on shares of Tempus AI in a research note on Friday, July 31st. Raymond James Financial set a $80.00 target price on shares of Tempus AI in a research report on Wednesday, September 2nd. The Goldman Sachs Group assumed coverage on shares of Tempus AI in a research note on Monday, September 21st. They issued a “neutral” rating and a $75.00 price target on the stock. BTIG Research boosted their price target on shares of Tempus AI from $70.00 to $80.00 and gave the stock a “buy” rating in a research report on Thursday, August 20th. Finally, Lake Street Capital downgraded shares of Tempus AI to a “hold” rating in a report on Monday, July 20th. Eleven equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $71.05.

Tempus AI Stock Down 5.1%

The business’s 50 day moving average price is $61.72 and its 200-day moving average price is $54.55. The company has a debt-to-equity ratio of 3.06, a quick ratio of 3.16 and a current ratio of 3.30. The firm has a market capitalization of $14.03 billion, a PE ratio of -53.98 and a beta of 3.72.

Tempus AI (NASDAQ:TEM) last issued its quarterly earnings data on Thursday, July 30th. The company reported ($0.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.10. The business had revenue of $382.49 million during the quarter, compared to analysts’ expectations of $379.69 million. Tempus AI had a negative return on equity of 50.28% and a negative net margin of 17.77%.The company’s revenue was up 21.6% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.22) earnings per share. As a group, equities research analysts forecast that Tempus AI, Inc. will post -1.38 earnings per share for the current year.

Insider Activity

In other news, EVP Andrew Polovin sold 2,951 shares of the company’s stock in a transaction dated Thursday, September 17th. The stock was sold at an average price of $75.00, for a total transaction of $221,325.00. Following the completion of the transaction, the executive vice president directly owned 135,189 shares of the company’s stock, valued at approximately $10,139,175. This represents a 2.14% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Ryan Fukushima sold 700 shares of the firm’s stock in a transaction that occurred on Wednesday, September 16th. The stock was sold at an average price of $70.00, for a total transaction of $49,000.00. Following the sale, the chief executive officer directly owned 15,874 shares in the company, valued at approximately $1,111,180. The trade was a 4.22% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 1,324,249 shares of company stock valued at $82,907,732. 24.26% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Tempus AI

Large investors have recently modified their holdings of the company. Sumitomo Mitsui Trust Group Inc. increased its position in Tempus AI by 23.4% in the 1st quarter. Sumitomo Mitsui Trust Group Inc. now owns 4,326,313 shares of the company’s stock valued at $195,636,000 after acquiring an additional 821,490 shares during the period. Amova Asset Management Americas Inc. increased its holdings in shares of Tempus AI by 23.4% in the first quarter. Amova Asset Management Americas Inc. now owns 4,326,313 shares of the company’s stock valued at $195,549,000 after purchasing an additional 821,490 shares during the period. Geode Capital Management LLC raised its stake in shares of Tempus AI by 8.2% during the fourth quarter. Geode Capital Management LLC now owns 1,870,510 shares of the company’s stock worth $110,478,000 after purchasing an additional 141,680 shares during the last quarter. Franklin Resources Inc. lifted its holdings in shares of Tempus AI by 27.9% during the fourth quarter. Franklin Resources Inc. now owns 1,861,782 shares of the company’s stock worth $109,938,000 after purchasing an additional 405,662 shares during the period. Finally, Norges Bank purchased a new position in Tempus AI in the 4th quarter valued at $48,234,000. 24.22% of the stock is owned by institutional investors and hedge funds.

Tempus AI Company Profile

Tempus AI, Inc is a technology company focused on applying artificial intelligence and data analytics to precision medicine. The company develops tools intended to help physicians make more informed treatment decisions by combining clinical information, molecular data and other health-related datasets.

Tempus provides genomic testing and diagnostic services, including sequencing and other molecular tests used primarily in oncology. Its platform also offers data and software solutions designed to support clinical research, pharmaceutical development, patient identification for clinical trials and the development of personalized treatment strategies.

Founded in 2015, Tempus is headquartered in Chicago and primarily serves healthcare providers, researchers and life sciences companies.